These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 19331709

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G, Lindgren P, Singh A, Klareskog L.
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.
    Kobelt G, Lindgren P, Geborek P.
    Scand J Rheumatol; 2009 Aug; 38(6):409-18. PubMed ID: 19922015
    [Abstract] [Full Text] [Related]

  • 5. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF.
    Arthritis Rheum; 2004 Dec 15; 51(6):964-73. PubMed ID: 15593319
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.
    Rheumatology (Oxford); 2006 Aug 15; 45(8):1029-38. PubMed ID: 16782734
    [Abstract] [Full Text] [Related]

  • 8. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J, Cohen JD, Combescure C, Bozonnat MC, Roch-Bras F, Lafon G, Daurès JP.
    Rheumatology (Oxford); 2009 Oct 15; 48(10):1236-41. PubMed ID: 19620209
    [Abstract] [Full Text] [Related]

  • 9. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R.
    Health Technol Assess; 2009 Sep 15; 13 Suppl 2():23-9. PubMed ID: 19804686
    [Abstract] [Full Text] [Related]

  • 10. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K.
    Rheumatology (Oxford); 2005 Sep 15; 44(9):1169-75. PubMed ID: 15956093
    [Abstract] [Full Text] [Related]

  • 11. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
    Lekander I, Kobelt G, Svarvar P, Ljung T, van Vollenhoven R, Borgström F.
    Value Health; 2013 Sep 15; 16(2):251-8. PubMed ID: 23538176
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A.
    Eur J Health Econ; 2010 Feb 15; 11(1):95-104. PubMed ID: 19967426
    [Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC.
    Arthritis Rheum; 2009 Mar 15; 61(3):291-9. PubMed ID: 19248130
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
    Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P.
    Int J Technol Assess Health Care; 2011 Jul 15; 27(3):193-200. PubMed ID: 21736857
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A, Conrad K, Baerwald C, König HH.
    Ann Rheum Dis; 2008 Oct 15; 67(10):1399-405. PubMed ID: 18192304
    [Abstract] [Full Text] [Related]

  • 16. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL.
    Rheumatology (Oxford); 2011 Jul 15; 50(7):1320-30. PubMed ID: 21371999
    [Abstract] [Full Text] [Related]

  • 17. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J.
    Mult Scler; 2008 Jun 15; 14(5):679-90. PubMed ID: 18566030
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L.
    Am J Geriatr Pharmacother; 2005 Jun 15; 3(2):77-86. PubMed ID: 16129384
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ, Brennan A, Ghatnekar O.
    Ann Rheum Dis; 2005 Jul 15; 64(7):995-1002. PubMed ID: 15550533
    [Abstract] [Full Text] [Related]

  • 20. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y, Trivedi D, Maclean R, Rosenblatt L.
    J Med Econ; 2010 Mar 15; 13(1):33-41. PubMed ID: 20001596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.